Presentation Type
Poster
Discipline Track
Clinical Science
Abstract Type
Research/Clinical
Abstract
Atezolizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds to programmed cell death-ligand 1 (PD-L1) and blocks interactions with the PD-1 and B7.1 receptors on activated T cells. It activates PD-L1/PD-1 pathway-mediated inhibition of the immune response, leading to activation of an anti-tumor effect. This drug is commonly used for urothelial cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, and hepatocellular cancer. Many side effects of this medication have been listed, but the most common cardiovascular effects are arrhythmia (1%), hypotension (5%), myocarditis (rare), and venous thromboembolism (4%). We present a case of new-onset, heart failure secondary to dilated cardiomyopathy secondary to atezolizumab in a patient with stage IV small cell lung cancer. With a growing number of these patients, a collaboration of oncologists, cardiologists, and immunologists is now necessary for a better characterization of the mechanisms of cardiotoxicity of this novel class of anticancer drugs, and for a comprehensive identification and management of patients at risk for cardiac adverse events. Prospective studies should assess whether chronic cardiotoxicity can occur after completion of therapy.
Academic/Professional Position
Resident
Mentor/PI Department
Internal Medicine
Recommended Citation
Garcia Cruz, Jian; Chouinard, Conrad; Gonzalez Morales, Elimar; Solis, Martha; and Pena, A., "The Cardiac Cost of Cancer Care: Atezolizumab-Induced Dilated Cardiomyopathy" (2024). Research Symposium. 63.
https://scholarworks.utrgv.edu/somrs/2024/posters/63
Included in
The Cardiac Cost of Cancer Care: Atezolizumab-Induced Dilated Cardiomyopathy
Atezolizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds to programmed cell death-ligand 1 (PD-L1) and blocks interactions with the PD-1 and B7.1 receptors on activated T cells. It activates PD-L1/PD-1 pathway-mediated inhibition of the immune response, leading to activation of an anti-tumor effect. This drug is commonly used for urothelial cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, and hepatocellular cancer. Many side effects of this medication have been listed, but the most common cardiovascular effects are arrhythmia (1%), hypotension (5%), myocarditis (rare), and venous thromboembolism (4%). We present a case of new-onset, heart failure secondary to dilated cardiomyopathy secondary to atezolizumab in a patient with stage IV small cell lung cancer. With a growing number of these patients, a collaboration of oncologists, cardiologists, and immunologists is now necessary for a better characterization of the mechanisms of cardiotoxicity of this novel class of anticancer drugs, and for a comprehensive identification and management of patients at risk for cardiac adverse events. Prospective studies should assess whether chronic cardiotoxicity can occur after completion of therapy.